2023-04-30 10:03:45
So far no in-depth research has been done regarding the effectiveness of the combined treatment with remdesivir and dexamethasone in subgroups of patients hospitalized due to the corona disease. In a study whose findings were published in the journal ‘Infectious Diseases’, the researchers tested the effectiveness of the combined treatment in hospitalized corona patients, while creating subgroups based on the basic characteristics of the patients.
More on a similar matter
For this purpose, the researchers conducted a retrospective cohort study in Denmark, which included 3,826 hospitalized corona patients between February 2020 and April 2021. The primary outcomes of the study were the use of invasive artificial respiration and the 30-day mortality rates, and a comparison of the outcomes was made between a cohort treated with remdesivir and dexamethasone and A previous cohort that did not receive this treatment. The researchers used inverse probability of treatment and logistic regression weighting in order to evaluate the relationships with progression to artificial respiration and the 30-day mortality rate between the two cohorts. The analyzes were conducted in general on the study population, as well as by subgroups based on patient characteristics.
The results of the study show that the odds ratio for progression to invasive ventilation and 30-day mortality in patients treated with remdesivir and dexamethasone, compared to the standard of care alone, was 0.46 (95% confidence interval, 0.37-0.57) and 0.47 (95% confidence interval, 0.37-0.57) -95% confidence 0.39-0.56), respectively. Elderly patients, overweight patients, and patients who required supplemental oxygen during hospitalization showed a reduced risk of mortality, regardless of the patient’s gender, the presence of co-morbidities, or the duration of symptoms.
In conclusion, patients treated with remdesivir and dexamethasone showed significantly improved results compared to patients treated with standard treatment only. These beneficial effects were observed in most subgroups of patients.
source:
Cæcilie Leding, Jacob Bodilsen, Christian Brieghel et al. (2023) Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone, Infectious Diseases, 55:5, 351-360, DOI: 10.1080/23744235.2023.2187081
#Improved #outcomes #corona #patients #treated #remdesivir #dexamethasone